Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma.
Krishnan
Ganapathy
G
Department of Internal Medicine, Division of Hematology and Oncology, Michigan State University, East Lansing, MI, USA.
D'Silva
Karl
K
Al-Janadi
Anas
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab